this author has yet to write their bio.
meanwhile lets just say that we are proud chen, chenyan contributed a whooping 385 entries.
eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.
eisai has grown smoothly since entering the chinese market in the early 1990s and the total …
lenvima® plus everolimus also showed statistically significant improvement in pfs and orr endpoints versus sunitinib
results of investigational phase 3 clear trial (study 307)/keynote-581 to be presented at upcoming medical meeting
if approved, aducanumab would become the first therapy to reduce the clinical decline of alzheimer’s disease and to meaningfully change the course of alzheimer’s disease
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (aβ) protofibril antibody lecanemab (development code: ban2401), at the 13th clinical trials on alzheimer’s disease (ctad) conference to be held virtually from november 4 to 7, 2020.
amgen and eisai to participate in the immune modulation domain of remap-covid, an adaptive clinical trial to test interventions for patients hospitalized with covid-19
amgen’s apremilast and eisai’s eritoran to be evaluated across multiple international trial sites within the remap network
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and cogstate, ltd. (headquarters: melbourne, australia and new haven, usa, ceo: brad o’connor, “cogstate”) announced today that the companies have entered into a collaboration whereby eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by cogstate, including the “cogstate brief batterytm” (cbb) for use in healthcare and other markets.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that biogen (nasdaq: biib) has disclosed its submission of the marketing authorization application (maa) to the european medicines agency (ema) for the review of aducanumab, an investigational treatment for alzheimer’s disease, as of october 2020 in its q3 2020 earnings press release issued on october 21. this maa is subject to validation of whether the ema accepts the application for review, which biogen plans to announce when notified.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (aed) fycompa® (product name in china: 卫克泰®, generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in china by the national medical products administration.
the university of tokyo (president: makoto gonokami, “the university of tokyo”) and eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “protein degradation drug discovery”. the research time span will last five years from october 1, 2020 to september 30, 2025.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a joint research agreement with four research organizations (kan research institute, national center for global health and medicine, nagasaki university, and yokohama city university) in japan concerning the “development of therapeutics to prevent the aggravation of the novel coronavirus infectious disease (covid-19)” (grant number: 20fk0108255), which is a research project with eisai as the representative research organization.
爱游戏app官网登录入口 copyright(c) 2011 eisai china lnc.all rights reserved.
021-62881220
本网站使用cookies以使您获得最佳的体验。为了继续浏览本网站，您需同意我们对cookies的使用。想要了解更多有关于cookies的信息，或不希望当您使用网站时出现cookies，请阅读我们的cookies声明！
we may request cookies to be set on your device. we use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
click on the different category headings to find out more. you can also change some of your preferences. note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
these cookies are strictly necessary to provide you with services available through our website and to use some of its features.
because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. you always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. but this will always prompt you to accept/refuse cookies when revisiting our site.
we fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. you are free to opt out any time or opt in for other cookies to get a better experience. if you refuse cookies we will remove all set cookies in our domain.
we provide you with a list of stored cookies on your computer in our domain so you can check what we stored. due to security reasons we are not able to show or modify cookies from other domains. you can check these in your browser security settings.
we also use different external services like google webfonts, google maps, and external video providers. since these providers may collect personal data like your ip address we allow you to block them here. please be aware that this might heavily reduce the functionality and appearance of our site. changes will take effect once you reload the page.
google webfont settings:
google map settings:
google recaptcha settings:
vimeo and youtube video embeds:
you can read about our cookies and privacy settings in detail on our privacy policy page.
privacy policy